mRNA
Concerns over vaccination links to heart inflammation are valid, a U.S. Centers for Disease Control and Prevention advisory committee announced this afternoon.
The two companies will assess the safety and immunogenicity of the vaccine candidate, which codes for the hemagglutinin protein in the A/H3N2 strain of the seasonal flu virus.
Over the past year, the world at large has become more familiar with mRNA technology. Now the world will be introduced to a new type of RNA-based medicine called eRNA.
BioNTech will open a state-of-the-art manufacturing facility in Singapore to support a global supply of mRNA-based vaccines and therapeutics.
Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.
Between the Moderna and Pfizer-BioNTech COVID-19 vaccines, there are two mRNA therapeutics on the market … the only two.
Anima Biotech’s strategic collaboration with Takeda Pharmaceutical, just announced today, uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class of therapies for neurological diseases.
Findings from a second interim analysis of a first-in-human Phase I/II clinical trial of Translate Bio’s CF mRNA candidate, MRT5005, show the drug did not significantly improve lung function in patients with CF.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
The data is continuing to come in on the various COVID-19 variants, and so far the news is pretty good.
PRESS RELEASES